Where Do We Stand in the Management of Oligometastatic Prostate Cancer? A Comprehensive Review.

Cancers (Basel) · 2022 · PMC9029666 · PMID 35454924

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Despite that the primary endpoint was not significant, OS in the RT arm for patients with low M1 burden (<5 bone metastases) showed a trend favouring RT.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.